Here are the key details to know:
1. Data is sparse on FMT’s efficacy and safety with issues beyond C.diff patients.
2. However, FMT may be a promising treatment for ulcerative colitis.
3. For treating IBD patients, the type of bacteria needed for each patient seems to be different, creating the need to multiple doses at different intervals.
4. An article in Gastroenterology and Hepatology detailed the possibility of a monolithic superstool to treat heterogeneous patients across a range of complex diseases.
More articles on gastroenterology:
IU receives $3.1M NCI grant for computer-simulated CRC treatment research: 3 details
Pass the hammer — RGI & MidAtlantic Endoscopy physicians take part in ASC construction project
AGA reaffirms commitment to transparent guideline-creation process — 5 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.